人N末端C型利钠肽前体检测试剂盒（酶联免疫法） 本产品仅供科研使用

NT-proCNP ELISA

• 已获CE认证
• 可采用尿液，细胞培养液和非人类样本
• 根据FDA、ICH、EMEA指南历经广泛验证
• 高灵敏度：0.7pmol/l(=90pg/ml)
• 低样本量：仅需20 μl

相关文献： 

• Dynamic response of C-type natriuretic peptide and its aminoterminal propeptide (NTproCNP) to growth hormone treatment in children with short stature. 
  Olney RC et al.,Clin Endocrinol,2016;85(4):561-8.
• Serum NT-proCNP levels increased after initiation of GH treatment in patients with achondroplasia/hypochondroplasia. 
  Kubota T et al.,Clin Endocrinol,2016;84(6):845-50.
• Rats deficient C-type natriuretic peptide suffer from impaired skeletal growth without early death. 
  

• Fujii T et al.,PloS One,2018;13(3):e0194812.

适用于： 

• Bone Disease骨疾病

  ---

  Skeletal development and growth defects (Bocciardi and Ravazzolo, 2009; Hisado-Oliva et al., 2018; Ko et al., 2015; Kubota et al., 2016; Olney et al., 2016, 2015; Prickett et al., 2013)

• Cancer肿瘤

  ---

  Prostate cancer (Lippert et al., 2015)

• Heart & Cardiovascular disease心血管疾病

  ---

  Coronary heart disease (Guclu et al., 2017; Prickett et al., 2017)

  ---

  Chronic heart failure (Cabiati et al., 2013)

  ---

  Postural tachycardia syndrome (Lin et al., 2015)

  ---

  Angina (Prickett et al., 2017; Volpe et al., 2015)

• Metabolic Disease代谢性疾病

  ---

  Obesity (Del Ry et al., 2016)

• Other其他

  ---

  Parkinson (Espiner et al., 2014; Woodward et al., 2017)

  ---

  Hepatitis related liver disease (Abdelkader et al., 2015)

  ---

  Cirrhosis (Koch et al., 2012)

  ---

  Complicated pregnancy and preeclampsia (Espiner et al., 2015; Reid et al., 2014)

  ---

  Sepsis (Koch et al., 2012; Tomasiuk et al., 2014)

  ---

  Literature 文献

  Mutations in C-natriuretic peptide (NPPC): a novel cause of autosomal dominant short stature.
  Hisado-Oliva, A., Ruzafa-Martin, A., Sentchordi, L., Funari, M.F.A., Bezanilla-López, C., Alonso-Bernáldez, M., Barraza-García, J., Rodriguez-Zabala, M., Lerario, A.M., Benito-Sanz, S., Aza-Carmona, M., Campos-Barros, A., Jorge, A.A.L., Heath, K.E., 2018. Genet. Med. Off. J. Am. Coll. Med. Genet. 20, 91–97.
  PMID: 28661490

  ---

  Evaluation of Pericardial Fluid C-Type Natriuretic Peptide Levels in Patients Undergoing Coronary Bypass Surgery.
  Guclu, O., Karahan, O., Karabacak, M., Yuksel, V., Huseyin, S., Mavitas, B., 2017. Thorac. Cardiovasc. Surg. 65, 311–314.
  PMID: 26962968

  ---

  C-Type Natriuretic Peptides in Coronary Disease.
  Prickett, T.C.R., Doughty, R.N., Troughton, R.W., Frampton, C.M., Whalley, G.A., Ellis, C.J., Espiner, E.A., Richards, A.M., 2017. Clin. Chem. 63, 316–324.
  PMID: 28062626

  ---

  Central and systemic C-type Natriuretic Peptide are both reduced in Parkinson’s Disease.
  Woodward, Z., Prickett, T.C.R., Espiner, E.A., Anderson, T.J., 2017. Parkinsonism Relat. Disord. 43, 15–19.
  PMID: 28673612

  ---

  C-type natriuretic peptide is closely associated to obesity in Caucasian adolescents.
  Del Ry, S., Cabiati, M., Bianchi, V., Caponi, L., Maltinti, M., Caselli, C., Kozakova, M., Palombo, C., Morizzo, C., Marchetti, S., Randazzo, E., Clerico, A., Federico, G., 2016. Clin. Chim. Acta Int. J. Clin. Chem. 460, 172–177.
  PMID: 27376982

  ---

  Serum NT-proCNP levels increased after initiation of GH treatment in patients with achondroplasia/hypochondroplasia.
  Kubota, T., Wang, W., Miura, K., Nakayama, H., Yamamoto, K., Fujiwara, M., Ohata, Y., Tachibana, M., Kitaoka, T., Takakuwa, S., Miyoshi, Y., Namba, N., Ozono, K., 2016. Clin. Endocrinol. (Oxf.) 84, 845–850.
  PMID: 26814021

  ---

  Dynamic response of C-type natriuretic peptide and its aminoterminal propeptide (NTproCNP) to growth hormone treatment in children with short stature.
  Olney, R.C., Salehi, P., Prickett, T.C.R., Lima, J.J., Espiner, E.A., Sikes, K.M., Geffner, M.E., 2016. Clin. Endocrinol. (Oxf.) 85, 561–568. 
  PMID: 27177682

  ---

  CLINICAL SIGNIFICANCE OF SERUM N-TERMINAL PRO C-TYPE NATRIURETIC PEPTIDE IN HEPATITIS C-RELATED CHRONIC LIVER DISEASES.
  Abdelkader, N.A., Zaki, M., Saad, W.E., Hamdy, G., Sabry, D., 2015. J. Egypt. Soc. Parasitol. 45, 219–226
  PMID: 26485840

  ---

  Effects of pre-eclampsia and fetal growth restriction on C-type natriuretic peptide.
  Espiner, E.A., Prickett, T.C.R., Taylor, R.S., Reid, R.A., McCowan, L.M., 2015. BJOG Int. J. Obstet. Gynaecol. 122, 1236–1243.
  PMID: 25846957

  ---

  Skeletal overgrowth syndrome caused by overexpression of C-type natriuretic peptide in a girl with balanced chromosomal translocation, t(1;2)(q41;q37.1).
  Ko, J.M., Bae, J.-S., Choi, J.S., Miura, K., Lee, H.R., Kim, O.-H., Kim, N.K.D., Oh, S.K., Ozono, K., Lee, C.-K., Choi, I.H., Park, W.-Y., Cho, T.-J., 2015. Am. J. Med. Genet. A. 167A, 1033–1038.
  PMID: 25728306

  ---

  Plasma C-type natriuretic peptide as a predictor for therapeutic response to metoprolol in children with postural tachycardia syndrome.
  Lin, J., Han, Z., Li, H., Chen, S.Y., Li, X., Liu, P., Wang, Y., Tang, C., Du, J., Jin, H., 2015. PloS One 10, e0121913.
  PMID: 25811760; PMCID: PMC4374798

  ---

  C-type natriuretic peptide and its precursor: potential markers in human prostate cancer.
  Lippert, S., Iversen, P., Brasso, K., Goetze, J.P., 2015. Biomark. Med. 9, 319–326.
  PMID: 25808436

  ---

  C-type natriuretic peptide plasma levels are elevated in subjects with achondroplasia, hypochondroplasia, and thanatophoric dysplasia.
  Olney, R.C., Prickett, T.C.R., Espiner, E.A., Mackenzie, W.G., Duker, A.L., Ditro, C., Zabel, B., Hasegawa, T., Kitoh, H., Aylsworth, A.S., Bober, M.B., 2015. J. Clin. Endocrinol. Metab. 100, E355-359.
  PMID: 25387261

  ---

  The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment.
  Volpe, M., Carnovali, M., Mastromarino, V., 2015. Clin. Sci. 130, 57–77.

  ---

  C-type natriuretic peptide in Parkinson’s disease: reduced secretion and response to deprenyl.
  Espiner, E.A., Dalrymple-Alford, J.C., Prickett, T.C.R., Alamri, Y., Anderson, T.J., 2014. J. Neural Transm. Vienna Austria 1996 121, 371–378.
  PMID: 24306276

  ---

  C-type natriuretic peptide in complicated pregnancy: increased secretion precedes adverse events.
  Reid, R.A., Prickett, T.C.R., Pullar, B.E., Darlow, B.A., Gullam, J.E., Espiner, E.A., 2014. J. Clin. Endocrinol. Metab. 99, 1470–1478.
  PMID: 24446655

  ---

  The prognostic value of concomitant assessment of NT-proCNP, C-reactive protein, procalcitonin and inflammatory cytokines in septic patients.
  Tomasiuk, R., Mikaszewska-Sokolewicz, M., Szlufik, S., Rzepecki, P., Lazowski, T., 2014. Crit. Care Lond. Engl. 18, 440.
  PMID: 25043511; PMCID: PMC4075259

  ---

  C-type natriuretic peptide transcriptomic profiling increases in human leukocytes of patients with chronic heart failure as a function of clinical severity.
  Cabiati, M., Sabatino, L., Caruso, R., Verde, A., Caselli, C., Prescimone, T., Giannessi, D., Del Ry, S., 2013. Peptides 47, 110–114.
  PMID: 23911666

  ---

  Acute inflammation in young children inhibits C-type natriuretic peptide.
  Prickett, T.C.R., Hector-Taylor, J., Olney, R.C., Darlow, B.A., Espiner, E.A., 2013. Pediatr. Res. 74, 191–195.
  PMID: 23732776

  ---

  Serum NT-proCNP concentrations are elevated in patients with chronic liver diseases and associated with complications and unfavorable prognosis of cirrhosis.
  Koch, A., Zimmermann, H.W., Baeck, C., Schneider, C., Yagmur, E., Trautwein, C., Tacke, F., 2012. Clin. Biochem. 45, 429–435.

  ---

  C-type natriuretic peptide and overgrowth.
  Bocciardi, R., Ravazzolo, R., 2009. Endocr. Dev. 14, 61–66.
  PMID: 19293575

  ---

  Comparison of serum and heparinized plasma samples for measurement of chemistry analytes.
  Miles, R.R., Roberts, R.F., Putnam, A.R., Roberts, W.L., 2004. Clin. Chem. 50, 1704–1706.
  PMID: 15331516